Drug Trial Radar · NCT06106828
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Nov 15, 2023
Primary completion
Jul 24, 2025
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Conditions
- Thyroid Eye Disease
Interventions
SatralizumabDrug
Satralizumab will be administered by SC injection.
PlaceboDrug
Placebo will be administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in the Active TED Population Who Achieved ≥ 2 Millimeters (mm) Reduction in Proptosis From Baseline at Week 24 in the Study EyeTime frame: At Week 24
Locations
41 sites in 10 countries. Site status is shown where the registry gives one.
Plastics-Orbit-Neuro
San Diego, California
Connecticut Eye Consultants, P.C.
Danbury, Connecticut
University of Illinois Eye and Ear Infirmary
Chicago, Illinois
Scheie Eye Institute
Philadelphia, Pennsylvania
Vanderbilt Eye Institute
Nashville, Tennessee
Retina Consultants of Texas
San Antonio, Texas
University of Alberta
Edmonton, Alberta, Canada
Toronto Retina Institute
Toronto, Ontario, Canada
Universite de Montreal - Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Peking Union Medical College Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Hospital of Ministry of Health
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Xi'an Fourth Hospital
Xi'an, China
CHU Nantes - Hotel Dieu
Nantes, France
CHNO Hopital des Quinze Vingts
Paris, France
Fondation Rothschild
Paris, France
Hadassah MC
Jerusalem, Israel
Rabin MC
Petah Tikva, Israel
Sheba medical center
Ramat Gan, Israel
Specjalistyczny Osrodek Okulistyczny Oculomedica
Bydgoszcz, Poland
Profesorskie Centrum Medyczne Spolka Z Ograniczona Odpowiedzialnoscia
Gdansk, Poland
AIBILI - Association for Innovation and Biomedical Research on Light
Coimbra, Portugal
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Chung-Ang University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Vall d Hebron
Barcelona, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Hospital Ramon y Cajal
Madrid, Spain
Hospital Universitario Clínico San Carlos
Madrid, Spain
Hospital Universitario Virgen de la Macarena
Seville, Spain
Hospital Universitario la Fe: Servicio de Oftalmologia
Valencia, Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Sussex Eye Hospital
Brighton, United Kingdom
Bristol Eye Hospital
Bristol, United Kingdom
Gartnavel General Hospital
Glasgow, United Kingdom
St James University Hospital
Leeds, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.